MAPT and Alzheimer disease: ApoE ε4 leads to the development of AD via various mechanisms, including increased aggregation and decreased amyloid-βpolypeptide clearance; increased tau phosphorylation; reduced glucose metabolism, vascular and mitochondrial dysfunctions; network excitability; neurodevelopmental differences [105,106].